Srilakshmi Ravula
| Title | Associate Professor |
|---|
| Institution | University of Arkansas for Medical Sciences |
|---|
| Department | Internal Medicine, College of Medicine |
|---|
| Division | Hospital Medicine |
|---|
| Address | S6/31 SHOREY 4301 W. Markham Mail Slot # 795 Little Rock AR 72205
|
|---|
| Phone | 501-320-7729 |
|---|
ORCID
.gif) | 0009-0003-6565-3715  |
|---|
| vCard | Download vCard |
|---|
|
|
|
Research 5UM1AI109565 (RAVULA, SRILAKSHMI)Feb 1, 2022 - Jan 31, 2028 NIH/Nat. Inst. of Allergy & Infectious Diseases - Pass Through: Benaroya Research Institute at Virginia Mason Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (IRB 274955) Role: Principal Investigator |
| 5UM1AI109565-09 (RAVULA, SRILAKSHMI)Feb 1, 2022 - Jan 31, 2028 NIH/Nat. Inst. of Allergy & Infectious Diseases - Pass Through: Benaroya Research Institute at Virginia Mason Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (IRB 274955) Role: Principal Investigator |
| 021IGAN17001 (RAVULA, SRILAKSHMI)Mar 31, 2021 - Mar 30, 2022 Travere Therapeutics A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, ACTIVE CONTROL STUDY OF THE EFFICACY AND SAFETY OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY (IRB 262333) Role: Principal Investigator |
| 021FSGS16010 (RAVULA, SRILAKSHMI)Mar 3, 2020 Retrophin, Inc. - Pass Through: IQVIA, Inc. No FP attached Role: Principal Investigator |
|
Same Department
People who are also in this person's primary department.
|